The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment
in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within
a time window of 3 to 9 h after stroke-symptom onset. In addition, it assessed safety and
tolerability of 3 doses of desmoteplase compared with placebo with special consideration of
intracranial hemorrhage and major systemic bleedings.